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Extended methods on costs 
Depreciation of equipment costs was addressed by assuming a five year lifetime with no 
salvage value, and the standard 3.5% annual discount rate. Antihypertensive treatment 
comprised drug costs and an annual clinical review. Drug therapy costs were calculated 
using the British National Formulary prices1 of the commonest generic drugs in each class 
(Ramipril, Amlodipine, Indapamide) weighted by the number of antihypertensive drugs 
individuals were on from the Health Survey for England.2 
An individual surviving an acute cardiovascular event entailed permanent quality of life 
reduction, increased costs and higher mortality risk with respect to the cardiovascular event 
experienced. The acute cost of a myocardial infarction (MI) is taken from a modelling study 
by Palmer and colleagues. Post MI costs were based on an updated cost taken from Taylor 
and colleagues. 3 The cost of an unstable angina event and costs post event were assumed 
to be 60% of the costs of MI. The cost of a stable angina event was assumed to consist of an 
outpatient cardiology assessment plus non-invasive imaging as a typical package of care.4 
Post stable angina costs comprised drugs based on relevant NICE guidance.1,5,6  
The cost of a Transient Ischaemic Attack (TIA) event is taken from a Lipids Health 
Technology Assessment report and consisted of tests and procedures from patients being 
assessed in outpatient clinics.7 Drug costs were included in the acute event based on 
recommended treatments based on NICE guidelines.1,6,8 Post-TIA only the cost of drugs was 
applied. The initial cost of stroke and post-event costs applied in the model was based on a 
UK study that looked at the cost of stroke over five years.9 
The costs and consequences of individuals with an earlier diagnosis and treatment in the 
HBPM, ABPM and PROOF-BP compared to CBPM were taken into account.  
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Age Years since birth   
Sex Male or female   
Clinic sBP  1st clinic reading   
sBP change  Difference between the 1
st and 
third consecutive clinic readings   
Pulse pressure 
Difference between systolic 
and diastolic pressure (1st clinic 
reading) 
  
BMI Weight divided by height (squared)   
Diagnosis of hypertension Previously recorded as hypertensive   
Duration of hypertension Time since first diagnosis in years   
Antihypertensive prescription Any currently prescribed antihypertensive medication   
History of Cardiovascular disease 
Cerebrovascular disease, MI, 
coronary heart disease, 
peripheral vascular disease or 
heart failure 
  
sBP= systolic Blood Pressure. dBP=diastolic Blood Pressure. BMI= Body Mass Index. 
MI=Myocardial Infarction. 
The full algorithm is available online as an interactive calculator here: 
https://sentry.phc.ox.ac.uk/proof-bp 
 
Table S2 PROOF-BP risk algorithm test characteristics 
Test Characteristics 
Adjusted clinic BP  
< 130/80mm Hg 
Adjusted clinic BP between 
130/80mm Hg & 144/89mm Hg 
Adjusted clinic BP 
≥ 145/90mm Hg 
Screening Clinic BP ≥ 140/90mm Hg    
False Negative (masked hypertension) 0 0 0 
False Positive (white coat hypertension) 0 0 40 
True Negative (normotension) 0 76 0 
True Positive (sustained hypertension) 0 209 304 
Screening Clinic BP between 130/80mm Hg & 140/90mm 
Hg    
False Negative (masked hypertension) 5 0 0 
False Positive (white coat hypertension) 0 0 5 
True Negative (normotension) 17 108 0 
True Positive (sustained hypertension) 0 165 13 
Screening Clinic BP between 120/70mm Hg & 140/90mm 
Hg    
False Negative (masked hypertension) 24 0 0 
False Positive (white coat hypertension) 0 0 5 
True Negative (normotension) 42 158 0 
True Positive (sustained hypertension) 0 191 13 
 
Table S3. Cohort split of 1000 patients with a clinic BP ≥ 130/80 mm Hg 
Patients screening clinic BP by age and gender PROOF-BP risk algorithm 
Age Sex Clinic BP 
≥140/90 
mm Hg 
Clinic BP between 






Put on ABPM 
(adjusted clinic BP 
between 130/80 mm Hg & 




BP ≥ 145/90 mm 
Hg) 
40 Male 586 414 38 695 267 
50 Male 680 320 32 637 331 
60 Male 763 237 24 596 380 
70 Male 849 151 16 564 420 
75 Male 895 105 11 534 455 
40 Female 620 380 44 699 257 
50 Female 659 341 39 669 292 
60 Female 847 153 16 596 388 
70 Female 821 179 19 572 409 
75 Female 943 57 6 528 466 
PROOF-BP=Predicting out-of-office blood pressure; ABPM=Ambulatory BP monitoring 
 
Table S4. Cohort split of 1000 patients with a clinic BP ≥ 120/70mm Hg 
Patients screening clinic BP by age and gender PROOF-BP risk algorithm 
Age Sex Clinic BP 
≥140/90mm 
Hg 
Clinic BP between 






Put on ABPM 
(adjusted clinic BP 
between 130/80mm Hg 
& 144/89mm Hg) 
Offered Treatment 
(adjusted clinic BP  
≥ 145/90mm Hg) 
40 Male 167 833 77 811 112 
50 Male 115 885 93 793 114 
60 Male 281 719 76 744 179 
70 Male 186 814 90 754 156 
75 Male 358 642 69 707 224 
40 Female 267 733 83 788 129 
50 Female 391 609 66 757 177 
60 Female 398 602 59 746 194 
70 Female 449 551 56 706 238 
75 Female 391 609 64 716 220 
PROOF-BP=Predicting out-of-office blood pressure; ABPM=Ambulatory BP monitoring 
 
Table S5. Cohort split of 1000 patients with a clinic BP ≥ 140/90mm Hg 
Patients screening clinic BP by age and 
gender 
PROOF-BP risk algorithm 







(adjusted clinic BP 
<130/80mm Hg) 
Put on ABPM 
(adjusted clinic BP between 
130/80mm Hg & 
144/89mm Hg) 
Offered Treatment 
(adjusted clinic BP  
≥ 145/90mm Hg) 
40 Male 1000 0 0 580 420 
50 Male 1000 0 0 536 464 
60 Male 1000 0 0 517 483 
70 Male 1000 0 0 513 487 
75 Male 1000 0 0 497 503 
40 Female 1000 0 0 612 388 
50 Female 1000 0 0 580 420 
60 Female 1000 0 0 551 449 
70 Female 1000 0 0 512 488 
75 Female 1000 0 0 509 491 
PROOF-BP=Predicting out-of-office blood pressure; ABPM=Ambulatory BP monitoring 
 
 Table S6: Initial misdiagnosis (including those with Masked Hypertension) per 1000 people with a clinic BP of 130/80mm Hg and above 
 False negatives False positives  False negatives False positives 




















40 years , Male     40 years , Female     
CBPM  151 26 0 220 CBPM  52 15 0 277 
HBPM  151 25 0 153 HBPM  52 15 0 192 
ABPM  151 1 0 11 ABPM  52 1 0 14 
PROOF-BP 7 1 2 56 PROOF-BP 3 0 2 70 
50 years, Male      50 years, Female      
CBPM  96 47 0 191 CBPM  54 29 0 247 
HBPM  96 46 0 133 HBPM  54 29 0 172 
ABPM  96 2 0 10 ABPM  54 1 0 12 
PROOF-BP 5 1 1 48 PROOF-BP 3 1 2 62 
60 years, Male      60 years, Female      
CBPM  63 61 0 183 CBPM  39 51 0 265 
HBPM  63 60 0 127 HBPM  39 51 0 184 
ABPM  63 3 0 9 ABPM  39 3 0 13 
PROOF-BP 3 1 1 46 PROOF-BP 2 1 1 67 
70 years, Male      70 years, Female      
CBPM  39 69 0 195 CBPM  45 68 0 186 
HBPM  39 69 0 135 HBPM  45 68 0 129 
ABPM  39 3 0 10 ABPM  45 3 0 9 
PROOF-BP 2 1 1 49 PROOF-BP 2 1 1 47 
75 years , Male     75 years , Female     
CBPM  27 81 0 174 CBPM  79 14 0 208 
HBPM  27 80 0 121 HBPM  79 14 0 144 
ABPM  27 4 0 9 ABPM  4 14 0 10 
PROOF-BP 1 2 1 44 PROOF-BP 2 1 0 52 
CBPM= Clinic Blood Pressure Monitoring. HBPM= Home Blood Pressure monitoring. ABPM= Ambulatory Blood Pressure Monitoring. PROOF-BP=Predicting out-of-office blood pressure. 
  
Table S7 Detailed breakdown of costs and events for Male Cohorts 
Strategy Cardiovascular events Life Years Costs 
 MI UA SA Stroke TIA Life years QALYS Diagnosis Treatment NT Check-ups MI UA SA Stroke TIA Costs 
40 years, Male                 
CBPM 124 54 161 81 27 43.309 43.309 £53 £2,026 £71 £3,268 £815 £180 £2,631 £71 £9,115 
HBPM 124 54 161 81 27 43.309 43.309 £65 £1,964 £79 £3,269 £815 £180 £2,630 £71 £9,073 
ABPM 124 54 161 81 27 43.310 43.310 £153 £1,619 £116 £3,267 £814 £180 £2,627 £71 £8,846 
PROOF-BP 121 53 158 80 26 43.350 43.350 £123 £2,068 £69 £3,170 £793 £175 £2,545 £69 £9,010 
50 years, Male                 
CBPM 111 50 151 82 26 34.268 26.942 £51 £1,669 £50 £2,566 £673 £156 £2,492 £66 £7,903 
HBPM 111 50 151 82 26 34.268 26.943 £61 £1,620 £56 £2,564 £673 £156 £2,491 £66 £7,870 
ABPM 110 50 151 82 26 34.271 26.951 £126 £1,373 £81 £2,556 £671 £155 £2,484 £65 £7,709 
PROOF-BP 109 49 148 80 26 34.301 27.014 £100 £1,664 £52 £2,500 £658 £152 £2,417 £63 £7,764 
60 years, Male                 
CBPM 94 45 125 80 24 25.485 19.854 £52 £1,277 £33 £1,814 £513 £112 £2,171 £54 £6,177 
HBPM 94 45 124 80 24 25.486 19.856 £60 £1,234 £39 £1,812 £513 £112 £2,168 £54 £6,147 
ABPM 94 45 124 80 24 25.492 19.868 £112 £1,046 £56 £1,804 £511 £112 £2,155 £53 £6,018 
PROOF-BP 93 44 122 79 23 25.511 19.903 £83 £1,229 £39 £1,777 £504 £110 £2,110 £52 £6,036 
70 years, Male                 
CBPM 75 37 91 73 19 17.488 13.583 £53 £896 £20 £1,176 £349 £68 £1,673 £37 £4,355 
HBPM 75 37 90 73 19 17.489 13.586 £60 £859 £25 £1,174 £348 £68 £1,669 £37 £4,328 
ABPM 75 37 90 72 19 17.496 13.599 £103 £718 £37 £1,164 £346 £67 £1,651 £36 £4,237 
PROOF-BP 74 37 89 71 19 17.504 13.613 £68 £823 £28 £1,152 £342 £67 £1,627 £36 £4,229 
75 years, Male                 
CBPM 65 32 77 71 17 14.008 10.814 £53 £735 £14 £893 £270 £53 £1,492 £29 £3,581 
HBPM 64 32 76 71 17 14.010 10.817 £59 £708 £17 £890 £269 £53 £1,486 £29 £3,558 
ABPM 64 32 76 70 16 14.015 10.829 £92 £615 £25 £880 £266 £52 £1,466 £29 £3,484 
PROOF-BP 63 32 75 69 16 14.019 10.836 £57 £682 £20 £873 £264 £52 £1,451 £29 £3,476 
CBPM= Clinic Blood Pressure Monitoring. HBPM= Home Blood Pressure monitoring. ABPM= Ambulatory Blood Pressure Monitoring. PROOF-BP=Predicting out-of-office blood pressure. MI= Myocardial infarction.  
UA= Unstable Angina. SA=Stable Angina.TIA= Transient Ischaemic Attack. QALY= Quality Adjusted Life Year. NT Check-ups = BP check-ups for those without a hypertension diagnosis 
  
 Table S8 Detailed breakdown of costs and events for Female Cohorts 
Strategy Cardiovascular events Life Years Costs 
 MI UA SA Stroke TIA Life years QALYS Diagnosis Treatment NT Check-ups MI UA SA Stroke TIA Costs 
40 years, Female                 
CBPM 46 26 103 85 21 44.002 34.543 £58 £1,885 £85 £997 £421 £112 £2,473 £53 £6,083 
HBPM 46 26 103 85 21 44.002 34.543 £74 £1,802 £95 £997 £422 £112 £2,473 £53 £6,028 
ABPM 46 27 104 85 21 44.000 34.540 £190 £1,342 £146 £999 £423 £112 £2,475 £53 £5,741 
PROOF-BP 45 26 101 83 21 44.020 34.583 £150 £1,838 £92 £978 £412 £110 £2,401 £52 £6,032 
50 years, Female                 
CBPM 45 23 96 85 20 34.856 26.634 £55 £1,537 £62 £927 £333 £98 £2,407 £47 £5,466 
HBPM 45 23 96 85 20 34.856 26.634 £68 £1,473 £70 £927 £333 £98 £2,408 £47 £5,423 
ABPM 45 23 96 85 20 34.856 26.634 £151 £1,158 £104 £928 £332 £98 £2,407 £47 £5,224 
PROOF-BP 44 23 94 83 19 34.874 26.672 £121 £1,494 £69 £908 £324 £95 £2,335 £45 £5,391 
60 years, Female                 
CBPM 41 17 74 82 17 25.899 19.364 £60 £1,291 £30 £755 £206 £66 £2,129 £37 £4,575 
HBPM 41 17 74 82 17 25.899 19.364 £72 £1,229 £38 £755 £206 £66 £2,129 £37 £4,532 
ABPM 41 17 74 81 17 25.901 19.368 £146 £955 £66 £754 £206 £66 £2,123 £37 £4,350 
PROOF-BP 41 17 73 80 17 25.910 19.385 £91 £1,145 £46 £744 £203 £65 £2,085 £36 £4,415 
70 years, Female                 
CBPM 33 12 50 73 15 17.700 12.949 £53 £840 £24 £509 £112 £38 £1,643 £28 £3,246 
HBPM 33 12 50 73 15 17.701 12.951 £60 £804 £28 £508 £112 £38 £1,639 £28 £3,217 
ABPM 33 12 50 72 15 17.706 12.958 £103 £668 £41 £504 £111 £37 £1,623 £28 £3,115 
PROOF-BP 33 12 49 71 15 17.712 12.970 £71 £783 £30 £497 £109 £37 £1,594 £27 £3,148 
75 years, Female                 
CBPM 28 9 41 67 14 14.153 10.141 £57 £726 £13 £383 £77 £28 £1,378 £25 £2,686 
HBPM 28 9 41 67 14 14.154 10.142 £64 £691 £18 £382 £76 £28 £1,373 £25 £2,658 
ABPM 28 9 41 66 14 14.158 10.149 £104 £574 £28 £378 £76 £28 £1,356 £24 £2,568 
PROOF-BP 28 9 40 66 14 14.159 10.152 £59 £641 £22 £376 £75 £28 £1,348 £24 £2,572 
CBPM= Clinic Blood Pressure Monitoring. HBPM= Home Blood Pressure monitoring. ABPM= Ambulatory Blood Pressure Monitoring. PROOF-BP=Predicting out-of-office blood pressure. MI= Myocardial infarction.  
UA= Unstable Angina. SA=Stable Angina.TIA= Transient Ischaemic Attack. QALY= Quality Adjusted Life Year. NT Check-ups = BP check-ups for those without a hypertension diagnosis 
 
  
Table S9 Number of Ambulatory Monitoring Investigations by PROOF-BP algorithm vs standard NICE ABPM strategy 
Screening clinic BP ≥130/80mm 





Underlying prevalence of 
Hypertension’ 
40 years, Male 695 586 109 152 178 330 
50 years, Male 637 680 -43 97 326 423 
60 years, Male 596 763 -167 63 424 488 
70 years, Male 564 849 -285 40 486 526 
75 years, Male 534 895 -361 28 570 598 
40 years, Female 699 620 79 53 107 160 
50 years, Female 669 659 10 54 201 255 
60 years, Female 596 847 -251 39 357 396 
70 years, Female 572 821 -249 45 476 521 
75 years, Female 528 943 -415 14 557 571 
Screening clinic BP ≥120/70mm 





Underlying prevalence of 
Hypertension’ 
40 years, Male 811 167 644 305 51 356 
50 years, Male 793 281 512 218 135 353 
60 years, Male 744 358 386 172 199 371 
70 years, Male 754 391 363 159 224 384 
75 years, Male 707 449 258 144 286 430 
40 years, Female 788 115 673 122 20 142 
50 years, Female 757 186 571 129 57 185 
60 years, Female 746 267 479 188 113 301 
70 years, Female 706 398 308 153 231 383 
75 years, Female 716 391 325 155 231 385 
Screening clinic BP ≥140/90mm 





Underlying prevalence of 
Hypertension’ 
40 years, Male 580 1000 -420 0 304 304 
50 years, Male 536 1000 -464 0 480 480 
60 years, Male 517 1000 -483 0 556 556 
70 years, Male 513 1000 -487 0 573 573 
75 years, Male 497 1000 -503 0 637 637 
40 years, Female 612 1000 -388 0 173 173 
50 years, Female 580 1000 -420 0 305 305 
60 years, Female 551 1000 -449 0 421 421 
70 years, Female 512 1000 -488 0 579 579 
75 years, Female 509 1000 -491 0 590 590 
  
Table S10 Sensitivity Analysis: Model entry restricted to clinic BP ≥ 120/70mm Hg results 
Strategy QALYs (95% CI)  Costs (95% CI) ICER Most CE 
strategy 
probability 
Strategy QALYs (95% CI) Costs (95% CI) ICER Most CE 
strategy 
probability 
40 years, Male     40 years, Female     
ABPM 18.084 (17.843 to 18.316) £3214 (£3119 to £3312)   0% ABPM 17.986 (17.789 to 18.186) £1822 (£1742 to £1917)   0% 
HBPM 18.079 (17.839 to 18.312) £3246 (£3154 to £3342) Dominated 0% HBPM 17.984 (17.788 to 18.184) £1846 (£1765 to £1938) Dominated 0% 
CBPM 18.078 (17.836 to 18.311) £3255 (£3161 to £3349) Dominated 0% CBPM 17.983 (17.787 to 18.184) £1852 (£1773 to £1943) Dominated 0% 
PROOF-BP 18.155 (17.925 to 18.381) £3395 (£3309 to £3488) £2521 100% PROOF-BP 18.016 (17.822 to 18.215) £2117 (£2031 to £2206) £9604 100% 
50 years, Male     50 years, Female     
ABPM 15.568 (15.309 to 15.805) £3300 (£3179 to £3432)   0% ABPM 15.408 (15.180 to 15.629) £2106 (£1991 to £2239)   0% 
HBPM 15.564 (15.304 to 15.801) £3339 (£3224 to £3462) Dominated 0% HBPM 15.406 (15.177 to 15.627) £2135 (£2025 to £2261) Dominated 0% 
CBPM 15.562 (15.302 to 15.800) £3350 (£3235 to £3471) Dominated 0% CBPM 15.405 (15.177 to 15.627) £2143 (£2036 to £2267) Dominated 0% 
PROOF-BP 15.632 (15.381 to 15.866) £3417 (£3311 to £3534) £1836 100% PROOF-BP 15.444 (15.217 to 15.661) £2308 (£2206 to £2421) £5553 100% 
60 years, Male     60 years, Female     
ABPM 12.817 (12.585 to 13.044) £3046 (£2880 to £3226)   0% ABPM 12.509 (12.295 to 12.735) £2173 (£1993 to £2366)   0% 
HBPM 12.811 (12.579 to 13.037) £3085 (£2924 to £3256) Dominated 0% HBPM 12.506 (12.291 to 12.733) £2205 (£2034 to £2394) Dominated 0% 
CBPM 12.810 (12.577 to 13.036) £3097 (£2941 to £3269) Dominated 0% CBPM 12.505 (12.290 to 12.731) £2214 (£2048 to £2397) Dominated 0% 
PROOF-BP 12.866 (12.640 to 13.091) £3128 (£2986 to £3290) £1669 100% PROOF-BP 12.549 (12.339 to 12.773) £2299 (£2145 to £2472) £3184 100% 
70 years, Male     70 years, Female     
ABPM 9.809 (9.580 to 10.005) £2509 (£2281 to £2748)   0% ABPM 9.352 (9.110 to 9.577) £1838 (£1608 to £2068)   0% 
HBPM 9.804 (9.573 to 10.000) £2544 (£2323 to £2773) Dominated 0% HBPM 9.349 (9.108 to 9.574) £1868 (£1644 to £2101) Dominated 0% 
CBPM 9.802 (9.571 to 9.999) £2556 (£2342 to £2785) Dominated 0% CBPM 9.348 (9.106 to 9.571) £1878 (£1655 to £2108) Dominated 0% 
PROOF-BP 9.843 (9.614 to 10.039) £2563 (£2361 to £2776) £1582 100% PROOF-BP 9.374 (9.133 to 9.597) £1919 (£1711 to £2129) £3674 100% 
75 years, Male     75 years, Female     
ABPM 8.229 (7.964 to 8.468) £2226 (£1989 to £2481)   0% ABPM 7.692 (7.411 to 7.939) £1579 (£1359 to £1840)   0% 
HBPM 8.225 (7.958 to 8.464) £2255 (£2028 to £2511) Dominated 0% HBPM 7.690 (7.409 to 7.936) £1602 (£1389 to £1852) Dominated 0% 
PROOF-BP 8.253 (7.987 to 8.487) £2264 (£2048 to £2494) £1674 100% CBPM 7.689 (7.409 to 7.936) £1611 (£1399 to £1859) Dominated 0% 
CBPM 8.223 (7.956 to 8.462) £2265 (£2037 to £2517) Dominated 0% PROOF-BP 7.708 (7.425 to 7.956) £1653 (£1454 to £1895) £4737 100% 
CI=Confidence Interval. CBPM= Clinic Blood Pressure Monitoring. HBPM= Home Blood Pressure monitoring. ABPM= Ambulatory Blood Pressure Monitoring. CE= cost-effective at £20,000 threshold. QALYs= quality-
adjusted life years. ICER= Incremental Cost Effectiveness Ratio. 
  
Table S11 Sensitivity Analysis: Model entry restricted to  clinic BP ≥ 140/90mm Hg results 
Strategy QALYs (95% CI)  Costs (95% CI) ICER Most CE 
strategy 
probability 
Strategy QALYs (95% CI) Costs (95% CI) ICER Most CE 
strategy 
probability 
40 years, Male     40 years, Female     
ABPM 18.146 (17.907 to 18.378) £3365 (£3226 to £3583)  0% ABPM 18.016 (17.813 to 18.207) £2140 (£2018 to £2337)  89% 
PROOF-BP 18.148 (17.909 to 18.381) £3407 (£3276 to £3598) £16551 76% PROOF-BP 18.019 (17.815 to 18.209) £2202 (£2082 to £2372) £29771 11% 
HBPM 18.147 (17.910 to 18.378) £3563 (£3440 to £3696) Dominated 24% HBPM 18.019 (17.816 to 18.210) £2389 (£2264 to £2521) Dominated 0% 
CBPM 18.148 (17.910 to 18.380) £3613 (£3515 to £3727) Dominated 0% CBPM 18.020 (17.817 to 18.210) £2452 (£2351 to £2567) Dominated 0% 
50 years, Male     50 years, Female     
ABPM 15.628 (15.381 to 15.861) £3524 (£3339 to £3750)  7% ABPM 15.435 (15.224 to 15.656) £2422 (£2254 to £2654)  18% 
PROOF-BP 15.630 (15.383 to 15.863) £3539 (£3373 to £3740) £8269 93% PROOF-BP 15.437 (15.226 to 15.658) £2449 (£2290 to £2658) £14314 82% 
HBPM 15.623 (15.378 to 15.857) £3661 (£3508 to £3825) Dominated 0% HBPM 15.436 (15.224 to 15.654) £2586 (£2438 to £2756) Dominated 0% 
CBPM 15.622 (15.378 to 15.857) £3696 (£3559 to £3838) Dominated 0% CBPM 15.437 (15.224 to 15.658) £2632 (£2500 to £2785) Dominated 0% 
60 years, Male     60 years, Female     
ABPM 12.850 (12.640 to 13.079) £3307 (£3077 to £3567)  10% ABPM 12.527 (12.304 to 12.745) £2425 (£2204 to £2714)  16% 
PROOF-BP 12.852 (12.641 to 13.080) £3311 (£3110 to £3558) £3265 90% PROOF-BP 12.529 (12.305 to 12.746) £2435 (£2222 to £2707) £8265 84% 
HBPM 12.841 (12.628 to 13.072) £3417 (£3233 to £3624) Dominated 0% HBPM 12.524 (12.304 to 12.739) £2548 (£2358 to £2788) Dominated 0% 
CBPM 12.839 (12.628 to 13.068) £3448 (£3279 to £3650) Dominated 0% CBPM 12.524 (12.301 to 12.740) £2586 (£2414 to £2804) Dominated 0% 
70 years, Male     70 years, Female     
PROOF-BP 9.820 (9.592 to 10.043) £2771 (£2530 to £3064) Dominant 93% PROOF-BP 9.349 (9.115 to 9.579) £2117 (£1870 to £2415) Dominant 94% 
ABPM 9.819 (9.591 to 10.043) £2777 (£2520 to £3090) Dominated 7% ABPM 9.348 (9.114 to 9.578) £2125 (£1866 to £2434) Dominated 6% 
HBPM 9.809 (9.580 to 10.033) £2866 (£2638 to £3134) Dominated 0% HBPM 9.341 (9.109 to 9.575) £2204 (£1977 to £2483) Dominated 0% 
CBPM 9.806 (9.577 to 10.027) £2895 (£2682 to £3154) Dominated 0% CBPM 9.340 (9.106 to 9.570) £2230 (£2003 to £2501) Dominated 0% 
75 years, Male     75 years, Female     
PROOF-BP 8.227 (7.968 to 8.456) £2498 (£2213 to £2857) Dominant 98% PROOF-BP 7.684 (7.424 to 7.931) £1864 (£1595 to £2206) Dominant 98% 
ABPM 8.227 (7.967 to 8.455) £2513 (£2224 to £2884) Dominated 2% ABPM 7.684 (7.424 to 7.930) £1877 (£1601 to £2230) Dominated 2% 
HBPM 8.217 (7.955 to 8.446) £2577 (£2301 to £2921) Dominated 0% HBPM 7.679 (7.418 to 7.926) £1939 (£1685 to £2272) Dominated 0% 
CBPM 8.214 (7.955 to 8.442) £2599 (£2333 to £2945) Dominated 0% CBPM 7.678 (7.418 to 7.925) £1961 (£1709 to £2280) Dominated 0% 
CI=Confidence Interval. CBPM= Clinic Blood Pressure Monitoring. HBPM= Home Blood Pressure monitoring. ABPM= Ambulatory Blood Pressure Monitoring. CE= cost-effective at £20,000 threshold. QALYs= quality-
adjusted life years. ICER= Incremental Cost Effectiveness Ratio. 
 
